Men and women-similar but not identical: Insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration

Leonard Kritharides, Stephen J. Nicholls

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Evaluation of: Fulcher et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385(9976), 1397-1405 (2015). A recent publication has explored the role of gender in determining the benefit from statins. Using data on 174,000 patients (including 46,000 women) collected up to 2010, a meta-analysis was performed using individual patient data, separately analyzing results for men and women and adjusting for baseline risk and nongender related risk factors. Over a median duration of follow-up of 4.9 years, statins reduced the risk of major vascular events by 21% for each mmol/l reduction of LDL cholesterol (relative risk: 0.79; 95% CI: 0.77-0.81; p < 0.001), reducing risk by 22% for men and 16% for women. There was no significant overall heterogeneity for the benefit achieved in men versus that achieved in women after adjusting for baseline risk. Baseline risk substantially affected the absolute number of events prevented, but did not affect the proportional benefit attributed to the use of statins. Total mortality was similarly and significantly reduced in men (10%) and women (9%). This study adds to existing literature in confirming that statins have demonstrable benefit in men and women.

Original languageEnglish
Pages (from-to)511-515
Number of pages5
JournalFuture Cardiology
Issue number5
Publication statusPublished or Issued - 1 Jan 2015


  • HMG CoA reductase
  • absolute risk
  • atherosclerosis
  • cardiac
  • cardiovascular
  • cholesterol
  • coronary
  • gender
  • review
  • statin
  • women

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this